SPRB

Spruce Biosciences Inc

Feb 20 • 12:33PM ET

51.41

-1.21 -2.30 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-84.76	Insider Own	16.88%	Shs Outstand	1.07M	Perf Week	-38.03%
Market Cap	55.03M	Forward P/E	-	EPS next Y	-32.34	Insider Trans	-0.00%	Shs Float	0.89M	Perf Month	-34.86%
Enterprise Value	45.71M	PEG	-	EPS next Q	-9.16	Inst Own	67.14%	Short Float	8.06%	Perf Quarter	-55.30%
Income	-47.88M	P/S	78.61	EPS this Y	78.05%	Inst Trans	25.14%	Short Ratio	1.07	Perf Half Y	514.22%
Sales	0.70M	P/B	5.38	EPS next Y	-52.25%	ROA	-119.08%	Short Interest	0.07M	Perf YTD	-40.98%
Book/sh	9.56	P/C	5.16	EPS next 5Y	38.81%	ROE	-167.93%	52W High	240.00 -78.58%	Perf Year	61.25%
Cash/sh	9.97	P/FCF	-	EPS past 3/5Y	10.79% -17.92%	ROIC	-813.44%	52W Low	4.28 1102.58%	Perf 3Y	-73.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.41%	Volatility	19.39% 10.88%	Perf 5Y	-96.51%
Dividend TTM	-	EV/Sales	65.29	EPS Y/Y TTM	-17.93%	Oper. Margin	-7100.00%	ATR (14)	7.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.54	Sales Y/Y TTM	-90.18%	Profit Margin	-6869.30%	RSI (14)	30.00	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	7.37%	SMA20	-30.63%	Beta	3.69	Target Price	205.75
Payout	-	Debt/Eq	0.25	Sales Q/Q	-100.00%	SMA50	-34.43%	Rel Volume	0.49	Prev Close	52.62
Employees	21	LT Debt/Eq	0.09	Earnings	Nov 10 AMC	SMA200	1.08%	Avg Volume	66.82K	Price	51.41
IPO	Oct 09, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-4.63% -	Trades		Volume	16,115	Change	-2.30%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-25	Initiated	Oppenheimer	Outperform	$283
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$160
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$254

Feb-18-26 07:00AM	Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -8.18%
Feb-17-26 04:05PM	Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire) -12.14%
Feb-05-26 04:05PM	Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -10.58%
Feb-03-26 08:00AM	Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team (Business Wire) +7.05%
Jan-28-26 08:00AM	Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium (Business Wire)
07:24AM	Loading…
Jan-21-26 07:24AM	Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences (Benzinga) +10.44%
Jan-18-26 07:02PM	Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration (PR Newswire)
Jan-08-26 08:00AM	Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital (Business Wire) -5.62%
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-15-25 08:00AM	Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors (Business Wire)
Nov-10-25 04:05PM	Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire) -8.97%
Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
09:44AM	Loading…
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ways Douglas Kirk	Interim Chief Medical Officer	Dec 11 '25	Option Exercise	0.00	1,250	0	1,250	Jan 21 04:04 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 15 '25	Option Exercise	0.00	1,009	0	8,447	Dec 17 04:58 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 15 '25	Option Exercise	0.00	2,676	0	14,922	Dec 17 04:56 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 11 '25	Option Exercise	0.00	1,900	0	8,296	Dec 12 07:05 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 10 '25	Option Exercise	0.00	514	0	6,580	Dec 12 07:05 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 11 '25	Option Exercise	0.00	4,950	0	15,192	Dec 12 07:03 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 10 '25	Option Exercise	0.00	1,196	0	10,670	Dec 12 07:03 PM
Gharib Samir M.	PRESIDENT AND CFO	Oct 20 '25	Option Exercise	0.00	2,053	0	6,727	Oct 22 04:15 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Oct 20 '25	Option Exercise	0.00	4,784	0	11,013	Oct 22 04:15 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 08 08:55 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 08 08:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRB

Spruce Biosciences Inc

Upgrade your FINVIZ experience